Publikationen, an denen er mitarbeitet CARLOS LOPEZ LARREA (67)

2024

  1. BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury

    Biomedicine and Pharmacotherapy, Vol. 174

  2. Inhibition of BRD4 Attenuates ER Stress-induced Renal Ischemic-Reperfusion Injury

    International Journal of Biological Sciences, Vol. 20, Núm. 5, pp. 1547-1562

2023

  1. BET Protein Inhibitor JQ1 Modulates Mitochondrial Dysfunction and Oxidative Stress Induced by Chronic Kidney Disease

    Antioxidants, Vol. 12, Núm. 5

  2. Type IV Collagen and SOX9 Are Molecular Targets of BET Inhibition in Experimental Glomerulosclerosis

    International Journal of Molecular Sciences, Vol. 24, Núm. 1

2022

  1. Ccn2 increases tgf‐β receptor type ii expression in vascular smooth muscle cells: Essential role of ccn2 in the tgf‐β pathway regulation

    International Journal of Molecular Sciences, Vol. 23, Núm. 1

  2. Demethylation of H3K9 and H3K27 Contributes to the Tubular Renal Damage Triggered by Endoplasmic Reticulum Stress

    Antioxidants, Vol. 11, Núm. 7

  3. Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination

    Frontiers in Immunology, Vol. 13

  4. Epigenetic Modulation of Gremlin-1/NOTCH Pathway in Experimental Crescentic Immune-Mediated Glomerulonephritis

    Pharmaceuticals, Vol. 15, Núm. 2

  5. Epigenetic networks driving T cell identity and plasticity during immunosenescence

    Trends in Genetics

  6. Kidney microRNA Expression Pattern in Type 2 Diabetic Nephropathy in BTBR Ob/Ob Mice

    Frontiers in Pharmacology, Vol. 13

  7. The CCN2 Polymorphism rs12526196 Is a Risk Factor for Ascending Thoracic Aortic Aneurysm

    International Journal of Molecular Sciences, Vol. 23, Núm. 23

2021

  1. Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia

    OncoImmunology, Vol. 10, Núm. 1

  2. Correction to: Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS‑CoV‑2 infectivity (Clinical Epigenetics, (2021), 13, 1, (187), 10.1186/s13148-021-01168-5)

    Clinical Epigenetics

  3. Defining a Methylation Signature Associated With Operational Tolerance in Kidney Transplant Recipients

    Frontiers in Immunology, Vol. 12

  4. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity

    Clinical Epigenetics, Vol. 13, Núm. 1

  5. Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity

    International Immunopharmacology, Vol. 98

2019

  1. Acute myeloid leukemia and NK cells: two warriors confront each other

    OncoImmunology, Vol. 8, Núm. 2

  2. Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

    Nucleic Acids Research, Vol. 47, Núm. 10, pp. 5016-5037

  3. Signal Integration and Transcriptional Regulation of the Inflammatory Response Mediated by the GM-/M-CSF Signaling Axis in Human Monocytes

    Cell Reports, Vol. 29, Núm. 4, pp. 860-872.e5

  4. Therapeutic Epigenetic Reprogramming of Trained Immunity in Myeloid Cells

    Trends in Immunology, Vol. 40, Núm. 1, pp. 66-80